Tag: newswire

Support Development of Dogecoin-Related Tools and Infrastructure

 The Star-Studded Kickoff Event Hosted by Nick Cannon and Jermaine Dupri featured a Performance by Social Media Pioneer Soulja Boy

XRP momentum is strong as the $5 price target comes into focus. PBK Miner’s new XRP mining contracts offer investors a unique opportunity for daily passive income and long-term asset growth.

BILLERICA, Mass., July 01, 2025 (GLOBE NEWSWIRE) -- E Ink (8069.TWO), the originator, pioneer, and global commercial leader in ePaper technology, announced the launch of a groundbreaking ePaper touchpad solution for laptops, developed through the integration of Intel^® Smart Base, Intel^® Innovation Platform Framework (Intel^® IPF), and Intel® AI Assistant Builder technologies. This innovative solution combines color ePaper with traditional laptop touchpads, creating a visual, AI-assisted human-machine interface (HMI) that enhances user interaction and brings a whole new dimension of functionality to Intel-based AI PCs.

FLORHAM PARK, N.J., July 01, 2025 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (Nasdaq: CLRB) (the “Company”), a late-stage clinical biopharmaceutical company focused on the discovery and development of drugs for the treatment of cancer, today announced the pricing of an underwritten public offering for gross proceeds of approximately $6 million prior to deducting underwriting commissions and offering expenses.

OMAHA, Neb., July 01, 2025 (GLOBE NEWSWIRE) -- TeleVox, the industry-leading provider of omnichannel patient relationship management platforms, is addressing the outreach gap in patient care with the launch of the Planned Outreach Program. This new solution, integrated within the award-winning TeleVox Practice Edition platform, is designed to drive patient engagement results for small practices with smart, automated outreach.

SARASOTA, Fla., July 01, 2025 (GLOBE NEWSWIRE) -- Oragenics, Inc. (NYSE American: OGEN), a company focused on developing unique, intranasal pharmaceuticals for the treatment of neurological disorders, today announced that it has entered into a placement agency agreement for the purchase and sale of up to 800,000 shares of the Company’s Series H Convertible Preferred Stock (“Preferred Stock”), no par value, and Warrants to purchase up to an additional 800,000 shares of Preferred Stock of the Company at an exercise price of $25.00 per share (the “Warrants”). The combined public Offering price of each share of Preferred Stock together with an accompanying Warrant is $25.00 (the “Offering”). The Preferred Stock is convertible into the Company’s common stock, par value $0.001 per share (the “Common Stock”), at a conversion price of $2.50 per share. The closing of the Offering is expected to occur on or about July 2, 2025, subject to the satisfaction of customary closing conditions.